ClinicalTrials.gg
RecruitingNCT06975332Updated Oct 13, 2026

Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression

An interventional study of Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT) in Glioblastoma, High-Grade Gliomas and Grade III Astrocytoma, sponsored by Medical University of Warsaw. Recruiting at 2 sites in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Medical University of Warsaw · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2024, registered Apr 2025).
  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Oct 13, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 21 studies in Glioblastoma with a site in Poland — 8 open to participants now, 10 under way, 1 of them phase 3. Glioblastoma · Poland.

Planned enrollment
16th of 20
35 · median 96
Started
2024
with 1 other
No phase
8 of 21
6 open now
Registered
17th of 21
by date
Lead sponsor
5 of 21
Medical University of Warsaw

Among the 21 studies in Glioblastoma with a site in Poland, this one is the 16th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2024, is one of 8 with no phase, and was the 17th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

8 of the 21 studies in Glioblastoma with a site in Poland are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Glioblastoma with a site in Poland, or all of them as a file.
02

Study summary

Brain tumors account for 1.35% of all cancers and cause 2.2% of cancer-related deaths. Gliomas are the most common type, comprising 40-90% of central nervous system tumors in different age groups. The incidence of malignant gliomas is approximately 0.5-2 per 100,000 people annually. Standard treatments include surgical resection, radiotherapy, and chemotherapy, yet overall survival remains low, typically 1-3 years post-diagnosis. The study highlights the pressing need for novel treatment strategies, particularly given the infiltrative nature of gliomas and the potential for targeted therapies using neuropeptides.

The aim of this study is to assess the efficacy and safety of local targeted therapy with [225Ac]Ac-DOTA-SP in recurrent glioblastoma.

It is an interventional study without a control group, initiated by the researcher. Patients included are aged 18-80 with recurrent WHO G3-G4 glioma post-first-line treatment, not requiring immediate surgery and meeting specific MRI progression criteria.

Patients will receive a maximum of six cycles of [225Ac]Ac-DOTA-SP, involving pre-treatment assessments, local administration of the agent after ensuring catheter patency, and continuous monitoring. Blood tests and neurological evaluations will be performed regularly.

Outcome will be assessed by measuring overall survival (OS) and progression-free survival (PFS). The study anticipates improvements in both OS and PFS when compared to current treatments, contributing to critical insights into targeted alpha therapy's effectiveness in glioblastoma.

Treatment with [225Ac]Ac-DOTA-SP previously indicated few significant side effects, primarily transient issues like seizures. Patients will be closely monitored throughout the study to identify any adverse effects promptly.

The estimated study duration is three years, with biological material collected for histopathological and genetic analysis during surgical reoperation.

Data will be anonymized to protect patient confidentiality, stored securely, and made available only for the scope of the study.

Led by Prof. Przemysław Kunert, the research team includes multiple co-investigators from neurosurgery and nuclear medicine departments.

Read the detailed description
  1. Background: Brain tumors account for 1.35% of all cancer conditions and cause deaths in 2.2% of cancer patients (Cancer Facts and Figures 2005). The most common type of brain tumors are gliomas. Depending on the age group, they account for 40%-90% of central nervous system tumors. The incidence of malignant gliomas is 0.5-2 per 100,000 people per year. Men are more frequently affected, usually in their 50s and 60s. In the Polish population, approximately 1300 people are diagnosed with gliomas annually, including about 600 cases of malignant gliomas. The standard treatment approach includes surgical treatment, radiotherapy, and chemotherapy. Despite the currently accepted treatment regimen, survival times-depending on the tumor type-range from 1 to 3 years.

    In a typical course, regardless of the therapy used, the extent of surgery, and other prognostic factors, the progression of the growth process occurs after some time. The use of chemotherapy extends survival time-depending on the tumor type-by several to several dozen weeks. This data indicates the need to seek other forms of treatment. Since brain gliomas are infiltrative in nature, it seems that an effective drug should exhibit the ability to diffuse freely within the tumor and specifically bind to cancer cells. Selected peptides exhibit such properties.

    One of the mechanisms regulating cell (including cancer cell) function involves receptor systems located in the cell membrane. These show high specificity of reaction with specific peptides. The expression of some receptor systems significantly increases in cells of specific tumor types. This property underlies the use of radioisotope-labeled peptides in diagnosis and treatment in oncology. Peptides bind to cancer cells, and ionizing radiation emitted by the attached radioisotope leads to regression of pathological changes. This method is developed only in a few centers worldwide and is currently used, among others, in treating certain types of lymphomas (anti-CD-20 antibody labeled with 90Y or 131I) and neuroendocrine tumors (somatostatin analogs labeled with 90Y, 177Lu).

    The benefit of this method is the ability to treat tumors that exhibit resistance to conventional chemotherapy and radiotherapy. Based on own experiences and literature data, it is known that gliomas show increased expression of selected receptor systems. In grade II-IV gliomas, a significant increase in expression for neurokinin-1 (NK-1) receptors, for which substance P is the ligand, has been noted. When administered directly to the tumor, substance P undergoes rapid diffusion and binding to glioma cells.

    At the center in Basel (Institute of Nuclear Medicine, University Hospital Basel), a derivative of substance P (1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid) was developed. It was shown that over 95% of gliomas exhibit significantly increased expression of the NK-1 receptor system, and that the proposed peptide has a capacity for specific binding to this type of receptor (out of 34 glioma tissue samples, 32 samples showed significantly increased NK-1 receptor system expression).

    Substance P can be labeled with various radioisotopes with differing physical properties, including 90Y and 177Lu-beta radiation emitters. The beta radiation emitted by 90Y has an energy of 2.1 MeV, with a tissue range of about 12 mm. Lutetium emits radiation with an energy of 497 keV, with a range of 1 mm. Limiting factors for the use of beta radiation include its range of action. There is a potential risk of damage to functionally critical brain centers if the tumor is located nearby. This was a premise for the use of alpha radiation emitters. One of the studied radioisotopes is 213Bismuth, which has an energy of 5.8 MeV but a range limited to only 81 μm.

    To date, within the framework of the project "Use of Radioisotope-Labeled Substance P in Treating Patients with Brain Tumors" (KB/204/A/201), local glioma treatment has been provided using substance P labeled with alpha emitters 213Bi and 225Ac in the case of confirmed disease recurrence.

    Initially, local treatment was performed using [213Bi]Bi-DOTA-SP at an activity of up to 11.2 GBq, achieving good treatment tolerance without clinically significant side effects. The progression-free survival (PFS) was 2.7 months, and the median overall survival (OS) after disease recurrence was nearly twice as long as expected in this patient group, amounting to 10.9 months. The median overall survival from diagnosis was 23.6 months. However, after the start of treatment with [213Bi]Bi-DOTA-SP, the median survival was 7.5 months.

    Considering the difficulties in labeling and quality control with a short half-life for 213Bi (46 min), the next step involved treatment with the alpha-emitter 225Ac. A study was conducted evaluating the determination of the maximum tolerated dose of [225Ac]Ac-DOTA-SP, administering activities of 10 MBq, 20 MBq, and 30 MBq. The treatment was well tolerated by patients, with predominantly mild and transient adverse effects such as seizures, aphasia, and hemiparesis. Most adverse effects occurred in patients treated with the 30 MBq dose of [225Ac]Ac-DOTA-SP; hence, the maximum tolerated dose was determined to be 20 MBq. Thrombocytopenia of grade 3 was observed in one study participant, and no grade 3 or 4 toxicity related to the treatment with [225Ac]Ac-DOTA-SP was reported in the other participants. The median OS from diagnosis was 35 months, and from recurrence, it was 13.2 months. The PFS from the start of treatment with [225Ac]Ac-DOTA-SP was 2.4 months.

    Studies showed that despite different physical properties (213Bi T1/2 = 46 minutes, 225Ac T1/ 2 = 9.9 days, with 225Ac decaying through alpha particles and 213Bi decaying only once), the survival data for patients treated with [225Ac]Ac-DOTA-SP and [213Bi]Bi-DOTA-SP are similar. Theoretically, the significantly longer half-life of 225Ac should allow for better distribution of [225Ac]Ac-DOTA-SP. The diffusion of the administered radiopharmaceutical is a critical factor for effective local therapy and depends on several factors, such as molecular weight, physicochemical properties, varying extracellular space density, and the post-resection cavity. Small vectors, such as modified SP (1800 Da), lead to rapid diffusion within tissues. However, subsequent administrations may increase the density of the extracellular space due to glioma scarring, leading to heterogeneous diffusion in subsequent injections of the radiopharmaceutical. A limiting factor for local treatment is the very slow rate of diffusion into brain tissue. The diffusion rate in the brain for most substances ranges from 0.15 to 0.6 mm/h. One possible cause could be increased tissue pressure within the tumor and surrounding tissues, which reduces the pressure gradient responsible for the diffusion process. It seems that enhanced diffusion could be achieved by employing forced diffusion via a slow infusion of 0.5 ml/hour of saline into the cavity immediately after administering the radiopharmaceutical. Overall results from both treatment arms exhibit a clear trend for prolonged survival compared to standard therapy.

    .

  2. Main Objective: To evaluate the efficacy of local targeted therapy with the alpha-emitter labeled neuropeptide [225Ac]Ac-DOTA-SP (TAT) using a forced diffusion method in cases of recurrence of glioma WHO G3-G4 after first-line treatment.

    Secondary Objective: To assess the safety of local targeted therapy with the alpha-emitter labeled neuropeptide [225Ac]Ac-DOTA-SP (TAT).

    .

  3. Study Design: Interventional study without a control group. The study is initiated by the investigator, and 225Ac is supplied based on a cooperation agreement between WUM and the Institute for Transuranium Elements (Karlsruhe).

    Sponsoring institution: Medical University of Warsaw (WUM). .

  4. Conducting the Study:

    1. Qualification visit - gathering a medical history, summarizing previous diagnostics and treatments - necessary documentation from the treatment course and imaging studies (CT scans and/or MRIs) must be provided. During the discussion, the doctor will provide all necessary information regarding the study and answer any questions.
    2. Reoperation with Catheter Placement:

      PET/CT scan using [68Ga]Ga-PSMA to indicate the site for biopsy and catheter placement.

      Resection with biopsy or just the biopsy of the tumor. Cathether placement (for lesions with a diameter >2 cm, up to 3 catheters may be placed). Catheter placement will take place at the Departments of Neurosurgery of either University Clinical Centre (UCK) or National Oncology Institute (NIO). This requires several days of hospitalization.

    3. Local Treatment with [225Ac]Ac-DOTA-SP:

      Treatment with [225Ac]Ac-DOTA-SP cannot begin earlier than 2 months after the conclusion of radiotherapy. Chemotherapy may be continued according to the oncologist's recommendations.

      Catheter patency controle about one week before planned treatment. Local administration of 5 MBq of 68Ga in a volume of 1-3 ml. Imaging of the brain using PET/CT Siemens Vision 600: 30 minutes after the administration of the tracer. For the first 3 patients, dual-day imaging with 68Ga and [68Ga]Ga-DOTA-SP will be performed to assess biodistribution: 5 MBq of 68Ga in a volume of 1-3 ml; 5 MBq of [68Ga]Ga-DOTA-SP in a volume of 1-3 ml.

    4. Conducting the Therapy:

    Patients will be treated with a maximum of 6 cycles of [225Ac]Ac-DOTA-SP. Preparation of the Radiopharmaceutical: The labeling procedure will be carried out at the Nuclear Medicine Department at WUM. The radioisotope 68Ga is available at the Nuclear Medicine Department; the department has a registered 68Ge/68Ga generator. The team of radiopharmacists at the department possess the necessary qualifications and have been performing radiopharmaceutical labeling using 68Ga for many years. 225Ac will be supplied based on a cooperation agreement between WUM and the Institute for Transuranium Elements (Karlsruhe). After labeling, the prepared product will undergo quality control to verify the labeling efficiency and radiopharmaceutical purity. In any case, if the labeling efficiency is below 90%, the product will not be administered to the patient.

    Therapy: Administered activity of [225Ac]Ac-DOTA-SP - 20 MBq in a volume of 10-20% of the resection cavity volume, maximum amount of SP 200 μg (combined for 68Ga and 225Ac).

    • 20-30 minutes before administering [225Ac]Ac-DOTA-SP, 250 ml of 15% mannitol, 500 ml of 0.9% NaCl, and 8 mg of dexamethasone will be administered intravenously.
    • Immediately after administering the therapeutic dose of [225Ac]Ac-DOTA-SP along with 5-10 MBq of [68Ga]Ga-DOTA-SP, brain imaging will be performed; acquisition time 1-2 minutes.
    • Connection of an infusion pump with saline and administration at a rate of 0.5 ml/hour for 2-4 hours.
    • After the infusion, 2-4 hours after administering [225Ac]Ac-DOTA-SP, brain imaging will be performed with an acquisition time lasting 4-8 minutes, and a whole-body scan: acquisition time approx. 10 minutes.

    Radioisotope treatment will be carried out in the UCK hospital, during hospitalization at the Department of Neurosurgery. The length of hospitalization will depend on the patient's condition; from previous experiences, this has typically been 3 days.

    Previous experiences have shown good tolerance to treatment with [225Ac]Ac-DOTA-SP. The only noted side effects during therapy were transient facial flushing, and some patients experienced seizures (all patients had seizures noted before therapy as well). For this reason, patients will be hospitalized for 24 hours after therapy in the Department of Neurosurgery (UCK).

    However, in the case of poor tolerance to experimental treatment, it will not be continued. Additionally, steroid therapy will be initiated (if it had not been previously). In the event of a seizure, standard anticonvulsant treatment will be applied.

    Blood and urine tests will be performed 1, 2, 4, and 24 hours after administering [225Ac]Ac-DOTA-SP.

    Assessment of Distribution of [225Ac]Ac-DOTA-SP via SPECT/CT Imaging:

    • SPECT/CT imaging at two time points: 4 hours after the administration of the therapeutic radiopharmaceutical (after PET/CT imaging is complete) and 24 hours after its administration.
    • SPECT/CT imaging will follow a quantitative protocol developed at the Nuclear Medicine Department (UCK) based on phantom studies, including about 30 minutes of SPECT imaging using multiple energy windows and approximately 3 minutes of CT imaging at reduced exposure parameters, performed to locate the accumulation of the radiopharmaceutical and correct for radiation attenuation.
    • Before each subsequent administration and 2-4 weeks after administering [225Ac]Ac-DOTA-SP:

    Laboratory tests: Hematology, AST, ALT, Na, K, creatinine, urea, CRP, INR, D-dimers.

    Assessment of the Karnofsky Performance Status (KPS). Barthel Index assessment. Assessment of adverse effects. f. Observation: The patient should remain hospitalized at the Department of Neurosurgery (UCK) for 24 hours after treatment with [225Ac]Ac-DOTA-SP.

    Physical examination, neurological assessment, adverse events. 24 and 48 hours after the first administration of [225Ac]Ac-DOTA-SP. MRI with contrast will be performed every 2 months to evaluate treatment efficacy and +/- 2 weeks before each administration of [225Ac]Ac-DOTA-SP.

    Follow-up visits (including telemedicine options) will be conducted according to Good Clinical Practice and the therapeutic strategy used in the research center, every 2 months during the first 18 months or depending on the clinical status of the patient.

    After 18 months, scheduled follow-up visits (including telemedicine options) will take place every 3 months or more frequently if needed.

    g. Discontinuation of Therapy: The occurrence of serious adverse events (according to the definition related to TAT).

    Coexisting illness preventing further treatment. Progression of the lesion. In the case of the appearance of a new symptomatic solitary lesion in the MRI, treatment may continue at the researcher's discretion, provided that the initially treated lesion or area is stable or regressing.

    Withdrawal of the patient from the study. Changes in the patient's condition that, in the investigator's opinion, make further treatment impossible.

    The investigator may decide to withdraw the patient from the study for unforeseen reasons, ensuring their safety.

    .

  5. Sample Size: The target sample size is 25 patients. Considering the possibility of patient dropouts, the group should include up to 35 patients. Patients will be recruited from those treated at the Departments of Neurosurgery (UCK, NIO).

    .

  6. Study Endpoints:

Primary: overall survival (OS) measured from the date of diagnosis.

Secondary: time to progression (progression-free survival, PFS), defined as:

  1. Clinical Progression: Clinical deterioration of performance status according to the Karnofsky scale or worsening of neurological function. The necessity of using or increasing the dose of corticosteroids by >50%.
  2. Progression on MRI:

Local progression within \< 4 cm from the border of the primary lesion after resection or, A new lesion on MRI or, Progression of the lesion on MRI by > 25% between two consecutive imaging studies.

In differential diagnostics, radiation necrosis should be included as a treatment-related effect (MRI perfusion and/or biopsy).

  • Expected Benefits of the Study: The expected outcome of the study is to assess the efficacy and safety of [225Ac]Ac-DOTA-SP with forced diffusion. It is anticipated that the proposed procedure should lead to an extension of survival time and time to disease progression compared to currently used therapeutic methods.

    .

  • Description of Risks and Discomforts for Study Participants: Based on current experiences with the treatment of [225Ac]Ac-DOTA-SP, no clinically significant side effects have been observed. The most frequently reported side effect was seizures (in all patients previously noted before therapy). No clinically significant side effects were identified in laboratory tests. There is no conclusive scientific evidence indicating that the administered local radioactivity poses a risk of developing cancer or hereditary defects. Current data suggest an extension of PFS and OS with the use of local treatment with [225Ac]Ac-DOTA-SP.

    .

  • Study Duration with Justification: The estimated duration of the study is 3 years. Patients who remain alive at the end of the study will be monitored until they report death.

    .

  • Biological Material: During reoperation and catheter placement, material will be collected for histopathological and genetic studies as per standard procedure.

    .

  • Patient Data Anonymization: No identifiable patient data will be stored alongside medical data subject to analysis. Patient medical data will be analyzed anonymously but will have an individual number corresponding to the anonymization list for each patient.
03

Conditions studied

  • Glioblastoma
  • High-Grade Gliomas
  • Grade III Astrocytoma
  • Grade III Glioma

Keywords

  • alpha emitter
  • glioblastoma recurrence
  • local therapy
  • 225-Ac
  • high-grade glioma recurrence
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age 18-80;
  • confirmed diffuse glioma (CNS WHO G3-G4);
  • after standard treatment with or resection, radiotherapy and/or chemotherapy;
  • tumour progression as defined by RANO 2.0 on MRI (hyperintense lesion on MRI or increase of maximal transverse diameter of tumour or increase on volumetric measurement, local progression by continuity in proximity of 4 cm to primary lesion after resection, stable lesion progression on MRI >25% in time between two consecutive MRIs or any new lesion on MRI; to differentiate progression from pseudoprogression a biopsy may be needed, especially within 12 weeks from radiotherapy);
  • unifocal lesion;
  • after resection: tumour volume \<50 ml AND tumour tissue thickness on contrast-enhanced T1 MRI \<1 cm;
  • after biopsy: tumour median diameter \<2 cm;
  • functional state >70 according to 's performance scale (KPS);
  • ability to give to participate in the study.

Exclusion criteria

Exclusion criteria:

  • necessity of urgent surgery (e.g., sudden increase in intracranial pressure);
  • significant postoperative complications: e.g., 's performance scale (KPS) \<70, wound infection, cerebrospinal fluid leak;
  • ventricular shunt leak >10% during a control patency test;
  • open/communicating resection cavity;
  • mass effect on CT scan or MRI with midline shift of more than 5 mm and/or nausea, vomiting, altered consciousness, or papilledema;
  • catheter obstruction;
  • predicted less than 3 months;
  • patients without preserved logical-verbal contact or uncooperative;
  • inability to provide informed, voluntary consent to participate in the study;
  • patients participating in another medical experiment;
  • patients who have taken any other drug within 1 month of the first dose;
  • prior treatment with [225Ac]Ac-DOTA-SP;
  • breastfeeding or pregnancy;
  • severe diseases of other organs that, in the opinion of the Investigator, significantly increase the risk of the procedure.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    High-grade glioma recurrence treated with alpha emitter [225Ac]Ac-DOTA-SP (TAT)

    Patients with high-grade gliomas (WHO G3-G4) recurrence who are treated with local, targeted therapy with alpha emitter \[225Ac\]Ac-DOTA-SP (TAT)

    Radiation: Local, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)

Interventions

  • RadiationLocal, targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP (TAT)

    Local, targeted therapy with alpha emitter \[225Ac\]Ac-DOTA-SP (TAT) administered to the post-resection cavity or tumour via Rickham reservoir using induced diffusion.

06

What researchers measure

Primary outcomes

  1. Number of patients experiencing clinical progression (as defined below)

    Clinical progression defined by: * reduction in Karnofsky Performance Scale result below 70% OR * new focal neurological deficit or exacerbation of existing deficit OR * necessity to use or increase dexamethasone dose by 50% or more.

    Time frame: From enrollment to 18 months

Secondary outcomes

  1. Number of patients experiencing radiological progression (as defined below)

    Radiological progression assessed on contrast-enhanced cerebral MRI: * any new contrast-enhanced lesion OR * 25% or more increase in contrast-enhancing lesions despite stable or increasing steroid dose OR * significant increase in non-enhancing FLAIR/T2W lesions, not attributable to other non-tumour causes.

    Time frame: From enrollment to 18 months

  2. Number of patients experiencing local radiological progression (as defined below)

    Local radiological progression assessed on contrast-enhanced cerebral MRI: * any new contrast-enhanced lesion within 4 cm from resection cavity OR * 25% or more increase in contrast-enhancing lesions within 4 cm from resection cavity despite stable or increasing steroid dose.

    Time frame: From enrollment to 18 months

07

Study locations

2 of 2 sites recruiting
  • Department of Neurosurgery, Medical University of Warsaw, Banacha 1a
    Warsaw, Poland 02-097, Poland
    Recruiting
    • Przemysław Kunert, Professor · Contactprzemyslaw.kunert@wum.edu.pl · +48 22 599 2575
    • Kacper Koczyk, MD · Contactkacper.koczyk@uckwum.pl · +48 22 599 2575
    • Przemysław Kunert, Professor · Principal investigator
    • Tomasz Czernicki, MD PhD · Sub investigator
    • Kacper Koczyk, MD · Sub investigator
  • Department of Neurosurgery, National Instiute of Oncology, W.K. Roentgena 5
    Warsaw, Poland 02-781, Poland
    Recruiting
08

References and documents

Publications

  • Hilario A, Ramos A, Perez-Nunez A, Salvador E, Millan JM, Lagares A, Sepulveda JM, Gonzalez-Leon P, Hernandez-Lain A, Ricoy JR. The added value of apparent diffusion coefficient to cerebral blood volume in the preoperative grading of diffuse gliomas. AJNR Am J Neuroradiol. 2012 Apr;33(4):701-7. doi: 10.3174/ajnr.A2846. Epub 2011 Dec 29. PubMed 22207304 ↗
  • Sykova E, Nicholson C. Diffusion in brain extracellular space. Physiol Rev. 2008 Oct;88(4):1277-340. doi: 10.1152/physrev.00027.2007. PubMed 18923183 ↗
  • Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, Muller-Brand J, Macke H, Reubi JC, Merlo A. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1335-44. doi: 10.1007/s00259-010-1385-5. Epub 2010 Feb 16. PubMed 20157707 ↗
  • Cordier D, Forrer F, Kneifel S, Sailer M, Mariani L, Macke H, Muller-Brand J, Merlo A. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I study. J Neurooncol. 2010 Oct;100(1):129-36. doi: 10.1007/s11060-010-0153-5. Epub 2010 Mar 10. PubMed 20217458 ↗
  • Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Pawlak D, Kulinski R, Rola R, Merlo A, Morgenstern A. Dose escalation study of targeted alpha therapy with [225Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacy. Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3595-3605. doi: 10.1007/s00259-021-05350-y. Epub 2021 Apr 15. PubMed 33860346 ↗
  • Krolicki L, Bruchertseifer F, Kunikowska J, Koziara H, Krolicki B, Jakucinski M, Pawlak D, Apostolidis C, Mirzadeh S, Rola R, Merlo A, Morgenstern A. Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):614-622. doi: 10.1007/s00259-018-4225-7. Epub 2018 Nov 29. PubMed 30498897 ↗
  • Krolicki L, Kunikowska J, Bruchertseifer F, Kulinski R, Pawlak D, Koziara H, Rola R, Morgenstern A, Merlo A. Locoregional Treatment of Glioblastoma With Targeted alpha Therapy: [ 213 Bi]Bi-DOTA-Substance P Versus [ 225 Ac]Ac-DOTA-Substance P-Analysis of Influence Parameters. Clin Nucl Med. 2023 May 1;48(5):387-392. doi: 10.1097/RLU.0000000000004608. Epub 2023 Mar 1. PubMed 36854309 ↗

Individual participant data

Plan to share: Yes — Study protocol and anonymised clinical, radiological and molecular data regarding individual patients will be made available as supplementary materials to published articles.

Supporting information: Study protocol

Time frame: from study conclusion in Sep 2027

Access criteria: Data access will be provided to any researchers possessing access to published articles as supplementary materials or via e-mail on reasonable request.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Sep 2027, 35 months after the start.

Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 35 months is below that.

Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Sep 2026 → Sep 2027 and completion Sep 2027 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2025
First posted
May 16, 2025
StartActual
Oct 9, 2024
Primary completionEst.
Sep 2027was Sep 2026
CompletionEst.
Sep 2028was Sep 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 Poland)
  • Department of Neurosurgery, Medical University of Warsaw, Banacha 1a · Warsaw, Poland
  • Department of Neurosurgery, National Instiute of Oncology, W.K. Roentgena 5 · Warsaw, Poland
Show 2 removed
  • Department of Neurosurgery, Medical University of Warsaw, Banacha 1a · Warsaw, Poland
  • Department of Neurosurgery, National Instiute of Oncology, W.K. Roentgena 5 · Warsaw, Poland
Oct 13, 2026
Primary completion
Sep 2026→Sep 2027
Oct 13, 2026
Study completion
Sep 2027→Sep 2028
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 Poland)
    • Department of Neurosurgery, Medical University of Warsaw, Banacha 1a · Warsaw, Poland
    • Department of Neurosurgery, National Instiute of Oncology, W.K. Roentgena 5 · Warsaw, Poland
    Show 2 removed
    • Department of Neurosurgery, Medical University of Warsaw, Banacha 1a · Warsaw, Poland
    • Department of Neurosurgery, National Instiute of Oncology, W.K. Roentgena 5 · Warsaw, Poland
    Primary completion Sep 2026→Sep 2027
    Study completion Sep 2027→Sep 2028
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06975332
Responsible party
Sponsor
First posted
May 16, 2025
Start date
Oct 9, 2024
Primary completion
Sep 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Przemysław Kunert, Professor
Contact
przemyslaw.kunert@wum.edu.pl
+48 22 599 2575
Przemysław Kunert, Professor
principal investigator · Department of Neurosurgery, Medical University of Warsaw, Poland
Joanna Kunikowska, Professor
study director · Department of Nuclear Medicine, Medical University of Warsaw, Poland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion